rnational's latest report, Orally Disintegrating Tablet and Film Technologies – Seventh Edition.
Key information presented in the report includes the growing Japanese generic market, ODTs in the emerging markets, ODT and OTF pipeline analysis, innovative developments for delivery of proteins and peptides via ODTs and OTFs, and new nutraceutical thin film technologies and products.
The report also includes a market analysis of both ODTs and OTFs, sales of leading ODT products in 2010-2011, ODT brand erosion by generics, late stage prescription OTFs, and the sales potential for OTFs with key APIs. Most importantly, the report contains screened and confirmed business and technology licensing opportunities from around the globe.
For complete report prospectus, pricing, and ordering information, please refer to:
About Technology Catalysts International:
Technology Catalysts International ("TCI") was founded in 1979 and provides consulting services in technology transfer and business research. The company specializes in technology licensing, technology assessment, and business intelligence. With a focus on pharmaceuticals, drug delivery, consumer healthcare, and advanced materials/processes, TCI's core consulting services are based on continuous monitoring of technological product development activities on a global basis. TCI is headquartered in the US and has offices in the UK, Germany, Czech Republic, China, Korea, Japan, India, and Latin America.
Ajay Rastogi , Vice President
Technology Catalysts International
Telephone (703) 531-0
Page: 1 2 3 Related medicine technology :1
|SOURCE Technology Catalysts International|
Copyright©2012 PR Newswire.
All rights reserved
. Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally2
. Mylan Launches Generic Version of Zyprexa® Tablets3
. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV4
. Mylan Launches Generic Version of Plavix® Tablets5
. Phase 3 Data Show NUCYNTA® ER (tapentadol) Extended-Release Tablets Provide Pain Management for Patients with Diabetic Peripheral Neuropathy (DPN)6
. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)7
. Mylan Launches Generic Version of Viramune® Tablets8
. Mylan Launches Generic Version of Bonviva® Film Coated Tablets in the UK and Italy9
. Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval in the treatment of adults with type 2 diabetes in Europe10
. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)11
. Qualitest Receives FDA Approval for Levetiracetam Extended-Release Tablets, 500mg and 750mg